Precision Decisions in NDMM: Live Virtual Rounds Preview

Precision Decisions in NDMM: Live Virtual Rounds Preview

Frontline treatment selection for newly diagnosed multiple myeloma (NDMM) is more complex than ever. With quadruplet regimens and anti-CD38 antibodies redefining the landscape, how do you choose the right therapy for each unique patient? In this exclusive preview, Ashley Chen, PharmD, BCOP (Fred Hutchinson Cancer Center), shares actionable insights on: 🔹The Nuances of Modern Selection: Balancing comorbidities and logistical hurdles. 🔹Managing Induction Burden: Proactive strategies for steroid side effects and neuropathy. 🔹Pragmatic Dosing: Finding the most sustainable, real-world dose for frail or older patients. 📅 Save Your Spot for the Live Event! Get case-based guidance from Dr. Rahul Banerjee, Dr. Ashley Chen, and Dr. Beth Faiman. Session 1: July 8 at 6:00 pm ET: https://bit.ly/3SitVaC Session 2: July 28 at 7:00 pm ET: https://bit.ly/4oIAcZo

Solving the PFIC Mystery: Genetic Testing and Diagnosis in Adults

Think PFIC is only a pediatric disease? Think again. Progressive Familial Intrahepatic Cholestasis (PFIC) was long considered a condition exclusive to children. However, breakthroughs in genomic sequencing are revealing a hidden population: adults with "unexplained" cholestasis who are actually living with undiagnosed PFIC variants. Early identification is the difference between manageable care and irreversible liver damage. In this interview episode Dr. Aparna Goel, Stanford School of Medicine, and Dr. Laura Bull, UC San Francisco, break down the adult phenotype of PFIC and how clinicians can close the diagnostic gap. What You'll Hear In This Episode: The Adult Phenotype: Why adult cases often present as "indolent" or mild compared to the severe jaundice seen in infants. Diagnostic Red Flags: When to move beyond standard autoimmune panels and look for genetic markers. Genetic Testing 101: A comparison of targeted gene panels vs. whole exome sequencing for the most efficient diagnosis. The Power of a Name: How a specific PFIC diagnosis changes everything—from family counseling to starting life-altering IBAT inhibitors. 💡 Earn 1.5 Free CME/AAPA Credits 👉 Join the Escape Room: i3health.com/pfic

New Frontiers in Esophagogastric Cancer with Dr. Yelena Janjigian

The treatment of esophagogastric cancer is undergoing a profound transformation. In this episode, Yelena Janjigian, MD (MSKCC), discusses how perioperative chemoimmunotherapy and precision biomarkers are redefining the standard of care. Key highlights include: - The Perioperative Shift: Why starting immunotherapy before surgery is achieving unprecedented pathologic responses. - Precision Testing: The essential role of MSI, PD-L1, HER2, and CLDN18.2 testing for every patient. - Avoiding Understaging: Why clinical evaluation must go beyond imaging to prevent missed therapeutic opportunities. - Multidisciplinary Success: The critical need for surgeon-oncologist communication before the first incision. Tune in to learn why "cure" is the new benchmark in localized disease and how to integrate these advances into your clinical practice today. Interested in the complete CE activity? Complete Module 1: https://bit.ly/45u106o Complete Module 2: https://bit.ly/3HtOziO

HER2-Mutant NSCLC Update: Expanded Approval of Zongertinib With Beth Sandy, MSN, CRNP, FAPO

Click here to view the full CME/NCPD/CPE/AAPA activity and hear additional insights on the HER2-mutant NSCLC treatment landscape! https://i3health.com/course-information/nsclc-advances The FDA’s recent expanded approval of zongertinib marks a significant milestone in the treatment of non-small cell lung cancer (NSCLC). As the first oral human epidermal growth factor receptor 2 (HER2) inhibitor to move into the frontline setting, this therapy offers a new standard of care for patients with metastatic or unresectable non-squamous NSCLC harboring HER2 mutations. Following the approval, Beth Sandy, Thoracic Oncology Nurse Practitioner at the University of Pennsylvania, sat down to explore its clinical implications, including efficacy data, side effect management, and the potential of having a once-daily oral pill for improving patient experiences.

The Future of Hemophilia: New Data, New Guidance, New Outcomes with Robert F. Sidonio, Jr., MD, MSc

Hemophilia care is evolving faster than ever. Dr. Robert Sidonio, Jr., a leading expert from Children’s Healthcare of Atlanta, joins us to discuss the latest breakthroughs in research and clinical trials. From navigating new treatment options to the importance of personalized patient selection, Dr. Sidonio shares the "real-world" perspective clinicians need to stay ahead. Listen now to discover what the future holds for hemophilia management! Click here to complete the activity, Raising the Bar for Hemophilia Management, and claim your CME credit: https://bit.ly/3Ini6vj